Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Baccarat, BioAlliance Pharma, Valeo: French Equity Preview

Sept. 22 (Bloomberg) -- Shares in the following companies may have unusual moves in Paris trading. Stock symbols are in parentheses and prices are from the last close.

France’s CAC 40 Index fell 1.6 percent to 2,935.82. The broader SBF 120 Index fell 1.4 percent to 2,259.25.

Baccarat SA (BCRA FP): The crystal manufacturer said its swung to a first-half net profit of 900,000 euros from a 611,000 euro year-ago loss. The shares rose 0.1 percent to 140.0 euros.

BioAlliance Pharma SA (BIO FP): The cancer drug developer said it had a first-half loss of 8.75 million euros, compared with net income of 10.58 million euros a year earlier. The shares fell 1.8 percent to 3.36 euros.

Neurones SA (NRO FP): The computer services company said first-half operating profit rose to 12.6 million euros from 10 million euros. The shares rose 0.4 percent to 7.28 euros.

Valeo SA (FR FP): The car parts maker said it bought back 558,302 shares at average price of 33.14 euros to cover bonuses and stock options plans. The shares fell 5 percent to 34.44 euros.

Vinci SA (DG FP): The construction company said it and Dutch builder Royal BAM Groep NV have finalized the financing for updating a section of the Berlin to Munich highway, a 220 million euro project. The shares fell 1.1 percent to 32.79 euros.

To contact the reporter on this story: Gregory Viscusi in Paris at gviscusi@bloomberg.net Marthe Fourcade in Paris at mfourcade@bloomberg.net

To contact the editor responsible for this story: Andrew Rummer at arummer@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.